Pharma & Biotech

Regulatory Science for Pharmaceutical Innovation and Internationalization Conference took place on April 28, 2024, sharing GBA market insights

China’s Center for Drug Evaluation has released its annual report for 2023.

NMPA overseas factory inspection results have seen at least three medical device manufacturers notified by the authorities this week alone...

China Greater Bay Area demand for medical products surges as Guangzhou customs supervised over 101 batches of imported products in 2023...

China’s Center for Drug Evaluation has issued updates to the requirements for the electronic submission of drug registration applications.

China’s CDE has issued guidelines to ensure accessibility for drug package inserts. It includes simplified and large-font format requirements.

China drug evaluation report 2022 was released by China’s Center for Drug Evaluation (CDE) in September 2023.

Breakfast seminar on health technology in Hong Kong and GBA will be carried out on November 27, 2023, at the Finland Chamber of Commerce.

Hong Kong new drug application, fulfilling the conditional requirements, will require one overseas marketing approvals instead of two.

Pre-Phase III drug clinical trial meeting guidelines have been released by the NMPA CDE for trial implementation as of March 22, 2023.

China’s Center for Drug Evaluation has released new Guidelines for Information on China Chemical Drug Instructions and Labels.

Oral solid dosage continuous manufacturing technical guidelines have been issued by the China CDE on Mar. 21, 2023, for trial implementation